Clinical trials: 5-Fluorouracil
Esophageal Cancer
CHFR Methylation Status Esophageal Cancer Study
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
- Trial name
- J10130 (NCT01372202)
- Testing
- Paclitaxel, Cisplatin, Oxaliplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Neoplasms
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
- Trial name
- HAIC，CRLM (NCT07024537)
- Testing
- FOLFOXIRI-based HAIC+Fuquinitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Meng Qiu
Breast Neoplasms
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.
- Trial name
- NCT07060807
- Testing
- Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tumor excision in BCS can…
- Trial name
- BCSMANC (NCT01917578)
- Testing
- Ultrasound, CNB, BCS, Modified Radical Mastectomy
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Colorectal Cancer Metastatic
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC…
- Trial name
- TriComB (NCT04564898)
- Testing
- Capecitabine, Bevacizumab, Trifluridine/Tipiracil
- Where
- 2 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Pancreatic Cancer
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs.
- Trial name
- NCT02581215
- Testing
- mFOLFIRINOX, Ramucirumab
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Walid Shaib, MD
Pancreatic Cancer
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
The investigators preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX and appears to be better tolerated.
- Trial name
- NCT02022033
- Testing
- FOLFOXA
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Brown University
Recurrent Rectal Cancer
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, two-cohort, phase II clinical trial. Patients aged 18 years or older who had pelvic recurrence rectal cancer with or without resectable distant metastasis, with treatment…
- Trial name
- TORCH-R (NCT05628038)
- Testing
- PD-1 antibody, Capecitabine, 5FU
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Metastatic Pancreatic Adenocarcinoma
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.
- Trial name
- NCT02985125
- Testing
- LEE011, Everolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Georgetown University
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
Potentially Resectable Hepatocellular Carcinoma
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion
This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled.
- Trial name
- HCC (NCT07738055)
- Testing
- Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping
Colorectal Neoplasms, Peritoneal Neoplasms
PIPAC for Peritoneal Metastases of Colorectal Cancer
This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol…
- Conditions
- Colorectal Neoplasms, Peritoneal Neoplasms, Appendiceal Neoplasms, Peritoneal Carcinomatosis
- Trial name
- CRC-PIPAC (NCT03246321)
- Testing
- repetitive ePIPAC-OX
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Koen Rovers
Squamous Cell Carcinoma
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Patients will be randomised after surgery, provided surgery is macroscopically adequate, that there is a flap of tissue protecting the vascular axis and that wound healing allows reirradiation to begin less than 8 weeks after…
- Trial name
- JANORL2 (NCT01211938)
- Testing
- single-fraction radiotherapy with concomitant 5FU and Hydrea, hyperfractionated radiotherapy with concomitant Cetuximab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastric Cancer Stage IV
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.
- Trial name
- NCT05319639
- Testing
- Oxaliplatin, Levo-Leucovorin, 5-fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Fujian Cancer Hospital
Adverse Drug Event, Colon Cancer
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).
- Conditions
- Adverse Drug Event, Colon Cancer, Breast Cancer, Pancreas Cancer
- Trial name
- NCT05266300
- Testing
- DPYD genotype
- Where
- Denmark
- Volunteers
- 722 people
- Sponsor
- University of Southern Denmark
Rectal Cancer
Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer
The primary objective was to improve adjuvant 5-FU chemoradiotherapy in resectable rectal cancer. The investigators hypothesis was that modulation of 5-FU by addition of either FA or INF-alpha may increase overall survival.
- Trial name
- FOGT1 (NCT01060501)
- Testing
- Folinic Acid, interferon-alpha
- Where
- Germany
- Volunteers
- 796 people
- Sponsor
- University of Ulm
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Pancreas Cancer
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.
- Trial name
- NCT04594772
- Testing
- Folfirinox, Gemcitabine, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.